Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-typeable Haemophilus influenzae (NTHi) antigens are surface molecules expressed by strains of Haemophilus influenzae lacking a polysaccharide capsule. These antigens, including outer membrane proteins (OMPs) like P6, adhesins such as HMW1 and HMW2, and lipooligosaccharides (LOS), mediate bacterial adhesion, colonization, and immune evasion. Due to significant antigenic variability between strains, developing broadly protective NTHi vaccines remains a challenge. NTHi is a major cause of respiratory tract infections, including otitis media, sinusitis, bronchitis, COPD exacerbations, and pneumonia, particularly in regions with widespread Hib vaccination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-typeable Haemophilus influenzae Antigen.